Table 3.
PSADT (months) | Before ADT
|
After ADT
|
||||||
---|---|---|---|---|---|---|---|---|
PSA (ng ml−1) | PSA (ng ml−1) | |||||||
0–4.9 | 5–9.9 | 10–19.9 | ≥20 | 0–4.9 | 5–9.9 | 10–19.9 | ≥20 | |
≥9 | 1 (1–2) | 1 (0–6) | 5 (2–15) | 3 (1–10) | 10 (8–13) | 17 (8–32) | 30 (21–40) | 39 (32–47) |
3–8.9 | 11 (9–14) | 10 (3–27) | 31 (16–53) | 24 (14–37) | 19 (16–22) | 30 (17–48) | 47 (36–58) | 57 (52–62) |
< 3 | 24 (11–43) | 22 (5–60) | 53 (26–79) | 44 (22–68) | 26 (20–33) | 40 (22–61) | 57 (45–69) | 67 (61–73) |
Abbreviations: ADT, androgen deprivation therapy; PSADT, PSA doubling time.